Igor Matushansky - Dec 21, 2021 Form 4 Insider Report for HOOKIPA Pharma Inc. (HOOK)

Role
Chief Medical Officer
Signature
/s/ Reinhard Kandera, as Attorney-in-Fact
Stock symbol
HOOK
Transactions as of
Dec 21, 2021
Transactions value $
-$34,938
Form type
4
Date filed
1/12/2022, 09:07 AM
Next filing
Feb 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HOOK Common Stock Options Exercise $808 +8.08K +10.44% $0.10* 85.5K Dec 21, 2021 Direct
transaction HOOK Common Stock Sale -$13.2K -5.3K -6.2% $2.49 80.2K Dec 21, 2021 Direct F1
transaction HOOK Common Stock Options Exercise $1.14K +11.4K +14.18% $0.10* 91.5K Dec 21, 2021 Direct
transaction HOOK Common Stock Sale -$18.5K -7.44K -8.13% $2.49 84.1K Dec 21, 2021 Direct F1
transaction HOOK Common Stock Options Exercise $341 +3.41K +4.05% $0.10* 87.5K Dec 21, 2021 Direct
transaction HOOK Common Stock Sale -$5.49K -2.21K -2.52% $2.49 85.3K Dec 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOOK Stock Option (Right to Buy) Options Exercise $0 -8.08K -100% $0.00* 0 Dec 21, 2021 Common Stock 8.08K $0.10 Direct F2
transaction HOOK Stock Option (Right to Buy) Options Exercise $0 -11.4K -80% $0.00 2.84K Dec 21, 2021 Common Stock 11.4K $0.10 Direct F3
transaction HOOK Stock Option (Right to Buy) Options Exercise $0 -3.41K -44.44% $0.00 4.26K Dec 21, 2021 Common Stock 3.41K $0.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
F2 25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 129,212 shares.
F3 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 42,624 shares.
F4 25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 9,373 shares.